Hepatitis C Clinical Trial
Official title:
A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Participants With Chronic Hepatitis C Virus Genotype 1
Verified date | August 2023 |
Source | Alexion |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate safety, tolerability, and antiviral response of ACH-0141625 compared to standard of care in hepatitis C virus (HCV)-positive participants.
Status | Completed |
Enrollment | 122 |
Est. completion date | April 2013 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males and females, aged 18 years and older - Chronic hepatitis C genotype 1 (as specified in the protocol) - Treatment naive - Females who are post-menopausal and amenorrheic must have a follicle-stimulating hormone (FSH) at screening. Females of childbearing potential must have a negative pregnancy test at screening and baseline. Females must use a non-hormonal method of contraception and must agree not to get pregnant during the study and for 6 months following the discontinuation of standard of care (SOC). - Fertile males must agree to use a condom and his female partner must agree to use 1 or more methods of contraception. Males must not donate sperm during the study and 3 months following the last exposure to RBV. Exclusion Criteria: - Body mass index (BMI) >36 kilograms (kg)/square meter (m^2) - Pregnant or nursing females or females of childbearing potential not willing to comply with contraceptive measures per protocol. Men whose female partners are pregnant or contemplating pregnancy. - Coinfection with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) - Other significant diseases including liver disease - History of drug or alcohol dependence or addiction within the past 6 months - History of participation in a clinical trial with a protease inhibitor or previous treatment with a protease inhibitor, where at least 1 dose of the protease inhibitor was consumed. - Use of herbal or homeopathic products, illicit drugs, cytochrome P450 (CYP) 3A4/5 substrates, inducers or inhibitors, hormonal methods of contraception, corticosteroids, immunosuppressive, or cytotoxic agents within 28 days of the first dose of study drug. - Have a clinically significant laboratory abnormality at screening (as specified in the protocol). - Segment 1: Participants with any history of decompensated liver disease defined as cirrhotic participants with a Child-Pugh score of > or = to 7. Segment 2: Participants who have had a liver biopsy that shows bridging fibrosis or cirrhosis. - Nonalcoholic steatohepatitis if ballooning degeneration or Mallory bodies are present on liver biopsy. - Participants who prematurely discontinued, interrupted, or dose reduced prior Peg-IFN and RBV therapy due to noncompliance or safety issues. - Encephalopathy or altered mental status of any etiology. - History of moderate, severe, or uncontrolled psychiatric disease (as specified in the protocol). - History of malignancy of any organ system treated or untreated within the past 5 years. - Use of colony stimulating factor agents within 90 days prior to baseline. - History of seizure disorder. - History of known coagulopathy including hemophilia. - Clinically of significant findings on fundoscopic or retinal examination at screening - History of immunologically mediate disease. - History of clinical evidence of chronic cardiac disease (as specified in the protocol) - Received concomitant systemic antibiotic, antifungals, or antivirals for the treatment of active infection within 14 days prior to the first dose of the study drug (as specified in the protocol) |
Country | Name | City | State |
---|---|---|---|
Belgium | Clinical Trial Site | Edegem | Antwerp |
Belgium | Clinical Trial Site | Gent | Oost-Vlaanderen |
Belgium | Clinical Trial Site | Haine-Saint-Paul | Hainaut |
United States | Clinical Trial Site | Arlington | Texas |
United States | Clinical Trial Site | Bradenton | Florida |
United States | Clinical Trial Site | Chicago | Illinois |
United States | Clinical Trial Site | Las Vegas | Nevada |
United States | Clinical Trial Site | Los Angeles | California |
United States | Clinical Trial Site | Los Angeles | California |
United States | Clinical Trial Site | New York | New York |
United States | Clinical Trial Site | Newport News | Virginia |
United States | Clinical Trial Site | Norfolk | Virginia |
United States | Clinical Trial Site | Orlando | Florida |
United States | Clinical Trial Site | Overland Park | Kansas |
United States | Clinical Trial Site | Philadelphia | Pennsylvania |
United States | Clinical Trial Site | Saint Louis | Missouri |
United States | Clinical Trial Site | San Antonio | Texas |
United States | Clinical Trial Site | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Alexion | Achillion, a wholly owned subsidiary of Alexion |
United States, Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Segment 1: Safety | Segment 1: Percentage of participants with the following: adverse events, abnormal laboratory safety tests, dose reductions, interruptions, and discontinuations. Criteria for abnormal laboratory safety tests: treatment-emergent worsening Division of AIDS (Acquired Immunodeficiency Syndrome) (DAIDs) graded laboratory tests. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. | 4 weeks | |
Primary | Segment 1: Rapid Viral Response At Week 4 (RVR4) | The primary efficacy endpoint for Segment 1 of the study was the percentage of participants in each treatment group achieving RVR4 (hepatitis C virus [HCV] ribonucleic acid (RNA) less than or equal to the limit of quantitation [LOQ] at the Week 4 visit). | 4 weeks | |
Primary | Segment 2: Safety | Segment 2: Percentage of participants with the following: adverse events, abnormal laboratory safety tests and dose reductions, interruptions and discontinuations. Criteria for abnormal laboratory safety tests: treatment-emergent worsening DAIDs graded laboratory tests. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. | 12 weeks | |
Primary | Segment 2: Complete Early Virologic Response (cEVR) | The primary efficacy endpoint for Segment 2 of the study was the percentage of participants achieving cEVR, defined as undetectable HCV RNA at Week 12. | Week 12 | |
Secondary | Segment 1: cEVR | For Segment 1, the percentage of participants in the virology population who achieved cEVR, defined as undetectable HCV RNA at Week 12. | 12 weeks | |
Secondary | Segment 2: RVR4 | For Segment 2, the percentage of participants in the virology population who achieved RVR4, defined as HCV RNA less than or equal to the LOQ at the Week 4 visit. | 4 weeks | |
Secondary | Segment 1 And Segment 2: End Of Treatment Response | The percentage of virology population participants who were reported as undetectable HCV RNA at the completion of treatment. | Week 48 (Segment 1); Week 24 (Segment 2) | |
Secondary | Segment 1 And Segment 2: Sustained Virologic Response 12 Weeks (3 Months Post-dosing) (SVR12) | The percentage of virology population participants who achieved sustained virologic response (SVR), defined as HCV RNA less than the LOQ, at 12 weeks (3 months) post-dosing. | 3 months post-dosing | |
Secondary | Segment 1 And Segment 2: Sustained Virologic Response 24 Weeks (6 Months Post-dosing) (SVR24) | The percentage of virology population participants who achieved SVR, defined as HCV RNA less than the LOQ, 6 months post-dosing. | 6 months post-dosing | |
Secondary | Segment 1 And Segment 2: HCV RNA Change From Baseline | The mean change from baseline in log10 HCV RNA level by visit for the virology population | Week 4 | |
Secondary | Segment 1 And Segment 2: HCV RNA Change From Baseline | Change from baseline in log10 HCV RNA level by visit. | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02869776 -
Integrating HCV and HIV Screening During the Era of HIV Antigen Testing
|
N/A | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 |